Combination therapy for the treatment of cancer
US11529339B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 30, 2019 |
| Grant date | Dec 20, 2022 |
| Priority date | — |
| Expiry date | Sep 30, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab. Additionally, provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab and dexamethasone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.